Further quantitative PCR studies revealed increased expression of NKX2-3 in a subset of patients with extranodal and splenic marginal-zone lymphomas (SMZLs), but not in other B-cell malignancies. Here, NKX2-3 is linked to splenic marginal zone lymphoma.